Covalent Fragment-Based Drug Discovery Platform at IRBM

About this poster

In this poster, we present IRBM’s custom-designed covalent fragment-based drug discovery platform, featuring a high-quality library of reversible and irreversible electrophilic warheads. Our "electrophile-first" approach enables effective mapping of nucleophilic pockets on challenging protein targets. With over half of the compounds assembled, this platform supports comprehensive screening and optimization, paving the way for the discovery of novel therapeutics and advancing the development of approved drugs.